A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2002
10/24/2002	WO2002083664A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083663A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083657A2 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
10/24/2002	WO2002083642A1 Compounds useful as anti-inflammatory agents
10/24/2002	WO2002083629A1 Bissulfonamide derivatives as inhibitors of dehydroquinate synthetases and type ii dehydroquinases
10/24/2002	WO2002083628A1 1,4-disubstituted benzo-fused compounds
10/24/2002	WO2002083627A2 Ligands des integrins avss6
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002083186A1 Nuclear receptor-mediated introduction of a pna into cell nuclei
10/24/2002	WO2002083180A1 Elongated and multiple spacers in activatible prodrugs
10/24/2002	WO2002083178A1 Pharmaceutical composition based on macrolides for topical application in ophthalmology
10/24/2002	WO2002083170A1 Vaccines including as an adjuvant type 1 ifn and processes related thereto
10/24/2002	WO2002083152A1 Activation of natural killer cells by adenosine a3 receptor agonists
10/24/2002	WO2002083143A1 Cxcr3 antagonists
10/24/2002	WO2002083121A1 Compositions for improving skin environment and clothes thereof
10/24/2002	WO2002083120A2 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
10/24/2002	WO2002083115A1 Treatment of disorders secondary to organic impairments
10/24/2002	WO2002083104A1 An effervescent solid composition of matter
10/24/2002	WO2002083103A2 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	WO2002083084A1 Nail compositions and methods of administering same
10/24/2002	WO2002083063A2 Method of improving systemic exposure of subcutaneously administered therapeutic proteins
10/24/2002	WO2002083060A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
10/24/2002	WO2002083059A2 Use of esters of long-chain fatty acids for treatment of autoimmune diseases
10/24/2002	WO2002058714A3 Methods and agents modulating upa/upar activity
10/24/2002	WO2002057226A9 68730 and 69112 protein kinase molecules and uses therefor
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002045570A9 Methods and compositions for the diagnosis and treatment of viral disease using 55092
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002032397A9 Electroprocessing in drug delivery and cell encapsulation
10/24/2002	WO2002030931A3 Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
10/24/2002	WO2002026726A3 Antiviral compositions and methods of use
10/24/2002	WO2002017935A3 A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
10/24/2002	WO2002000650A3 Novel compounds possessing antibacterial, antifungal or antitumor activity
10/24/2002	WO2001076568B1 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	WO2001055337A3 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
10/24/2002	US20020157124 Transgenic rodents and rodent cell lines expressing HIV co-receptors
10/24/2002	US20020156585 Crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (S. aureus MurB)
10/24/2002	US20020156264 And method of using the carboxypeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in carboxypeptidase-related disorders
10/24/2002	US20020156261 Wherein secondary structure disintegrates upon attachment of the oligonucleotide to a target nucleic acid; anticarcenogenic agents, treatment of Ewing's sarcoma
10/24/2002	US20020156251 Fusion protein for use in the treatment and prevention of viral diseases
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds
10/24/2002	US20020156102 Piperidine amides as modulators of chemo kine receptor activity
10/24/2002	US20020156094 Sulfonamide interleukin-1beta converting enzyme inhibitors
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156079 Antiulcer, antibacterial activity against Helicobacter pylori
10/24/2002	US20020156072 Thiazine oxazolidinone
10/24/2002	US20020156030 Heterocyclic aromatic compounds and uses thereof
10/24/2002	US20020156028 Macrolide antiinfective agents
10/24/2002	US20020156027 Ketolide antibiotics
10/24/2002	US20020156024 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
10/24/2002	US20020156017 Antimicrobial peptides and methods of use thereof
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155997 Biologically active material isolated from non-pathogenic bacteria, such as Enterobacteriaceae
10/24/2002	US20020155609 Monocyte-specific particulate delivery vehicle
10/24/2002	US20020155547 Polypeptide for use in the treatment of cancer, hepatitis, multiple sclerosis, fibrosis, inflammatory or autoimmune diseases, cancers and viral diseases
10/24/2002	US20020155537 Method for making heteromultimeric polypeptides
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155519 Human blood bacterium
10/24/2002	US20020155467 Detecting preferential polymorphism in sample; obtain nucleotide sequence sample, incubate with probe, detect signal, presence of signal indicates polymorphism
10/24/2002	US20020155434 Fusion protein for use in the treatment of viral diseases
10/24/2002	US20020155433 Polypeptide for use the prevention of infections associated with tissue grafting
10/24/2002	US20020155431 Screenining and detection of antiproliferative agentst; obtain tumor cells, incubate with antiproliferative agents, monitor reduction in tumor activity
10/24/2002	US20020155428 Retrovirus from the HIV group and its use
10/24/2002	US20020155153 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
10/24/2002	US20020155141 Pharmacologically acceptable solvent vehicles
10/24/2002	US20020155134 Dermatomycosis vaccine
10/24/2002	US20020155132 Administering an effective amount of a lytic peptide for therapy of immunodeficiency virus infection in an infected animal
10/24/2002	US20020155130 To immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus, bovine immunodeficiency virus or simian immunodeficiency virus
10/24/2002	US20020155127 Genetic vaccine against human immunodeficiency virus
10/24/2002	US20020155122 Immunologically significant herpes simplex virus antigens and methods for identifying and using same
10/24/2002	US20020155121 Virus coat protein/receptor chimeras and methods of use
10/24/2002	US20020155115 Cancer therapy
10/24/2002	US20020155097 For therapy and prophylaxis of cancer and tumors
10/24/2002	US20020155094 Method of treating sepsis and ARDS using chemokine beta-9
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	DE10119804A1 New peptides produced in primates during inflammation and sepsis, useful for diagnosis and treatment of these diseases, and their related antibodies
10/24/2002	CA2763637A1 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
10/24/2002	CA2490819A1 Compounds useful as anti-inflammatory agents
10/24/2002	CA2446921A1 Selective covalent-binding compounds having therapeutic diagnostic and analytical applications
10/24/2002	CA2445990A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	CA2444632A1 Vascular endothelial growth factor 2
10/24/2002	CA2444548A1 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2444164A1 Pufa polyketide synthase systems and uses thereof
10/24/2002	CA2444133A1 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
10/24/2002	CA2444047A1 Methods to inhibit viral replication
10/24/2002	CA2443912A1 Vaccines including as an adjuvant type 1 ifn and processes related thereto
10/24/2002	CA2443897A1 Transporters and ion channels
10/24/2002	CA2443874A1 Intermediates and enzymes of the non-mevalonate isoprenoid pathway
10/24/2002	CA2443732A1 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
10/24/2002	CA2443697A1 1,4-disubstituted benzo-fused compounds
10/24/2002	CA2443655A1 Tropane alkaloid multidrug resistance inhibitors from erythroxylum pervillei and use of the same
10/24/2002	CA2443563A1 Nail compositions and methods of administering same
10/24/2002	CA2443525A1 Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis c virus infections
10/24/2002	CA2443493A1 Surface proteins of streptococcus pyogenes
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443471A1 An effervescent solid composition of matter
10/24/2002	CA2443468A1 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	CA2443408A1 Kinases and phosphatases

1 ... 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 ... 1798